Acute Ischemic Stroke
Conditions
Keywords
Tenecteplase, Thrombolysis, diffusion weighted imaging, fluid attenuated inversion recovery
Brief summary
The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are: 1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch? 2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch. Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients. Participants will be randomly assigned (1:1) immediately after randomization: * Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg). * Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.
Detailed description
Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours. In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well \>4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain. TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.
Interventions
DRUGTNK-tPA
TNK-tPA (0.25 mg/kg, to maximum of 25mg)
DRUGAspirin
Asprin (300mg)
DRUGPlacebo
Asprin (placebo)
Sponsors
The First Affiliated Hospital of Zhengzhou University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
TNK group: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) and asprin (placebo) Control group: Asprin (300mg) plus TNK (placebo)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years; 2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed); 3. Imaging criteria: 1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR; 2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory; 4. NIHSS score 4-25; 5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1); 6. Signed informed consent from the patient or legally authorized representative.
Exclusion criteria
1. Planned endovascular treatment; 2. Contradictory to MRI examination; 3. MRI image not qualified for evaluation; 4. Serious neurological deficits before onset (mRS≥2); 5. Obvious head injuries or strokes within 3 months; 6. Subarachnoid or intracranial hemorrhage; 7. History of intracranial hemorrhage; 8. Intracranial tumor, arteriovenous malformation or aneurysm; 9. Intracranial or spinal cord surgery within 3 months; 10. Active internal hemorrhage; 11. platelet count of \<100000/mm3; 12. Aortic arch dissection; 13. Heparin therapy within 24 hours; 14. Oral warfarin is being taken and INR\>1.6 or APTT abnormal; 15. Oral anticoagulation therapy; 16. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg; 17. Blood glucose \< 50 mg/dl (2.7mmol/L); 18. Pregnancy; 19. Neurological deficit after epileptic seizures; 20. Major surgery within 1 month; 21. Gastrointestinal or urinary tract hemorrhage within the previous 30 days; 22. Myocardial infarction within 3 months; 23. Allergy to study drugs; 24. Unlikely to adhere to the trial protocol or follow-up; 25. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; 26. Participation in other interventional clinical trials within the previous 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modified Rankin Scale (mRS) | 90 ± 7 days | Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Modified Rankin Scale (mRS) | 90 ± 7 days | Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days. |
| National Institutes of Health Stroke Scale (NIHSS) | 24 hours and 7 days | NIHSS change from baseline at 24 hours and 7 days. |
| Barthel (BI) | 90 ± 7 days | Barthel Index score at 90 ± 7 days. |
| EuroQol 5-Dimension (EQ-5D) | 90 ± 7 days | Quality of life measured by EQ-5D scale at 90 ± 7 days. |
Countries
China
Contacts
CONTACTBo Song, MD
STUDY_CHAIRBo Song, MD
Department of Neurology, the First Affiliated Hospital of Zhengzhou University
Outcome results
None listed